Targeting PARP1, a binding partner of SOX2, emerges as a promising therapeutic strategy for individuals with elevated SOX2 levels, offering potential avenues for ESCC treatment [86]. The gene discussed is PARP1; the disease is esophageal squamous cell carcinoma.